AmeriWater, a leading provider of advanced water purification systems for healthcare, is pleased to announce it has signed an agreement with Vizient®...
-Novotech, a globally recognized full-service clinical research organization (CRO), is proud to have partnered with Chia Tai Tianqing Pharmaceutical Grou...
Scenic Biotech, a pioneer in modifier therapies for severe diseases, announced a license and research agreement with Alnylam Pharmaceuticals, Inc. (NASDA...
Hongene Biotech Corporation, a contract development and manufacturing organization (CDMO) specializing in nucleic acid therapeutics, entered a non-exclus...
When it comes to the field of computational biology, rProteins and bioinformatics fit together almost like a lock and key. Recombinant protein techn...
Idorsia Ltd (SIX: IDIA) announces that its novel dual endothelin receptor antagonist (ERA), TRYVIO™ (aprocitentan), has been included in the new co...
HUTCHMED (China) Limited announces the completion of patient enrollment of SANOVO, a China Phase III study of ORPATHYS® (savolitinib) and TAGRI...
-CILA Therapeutics has been awarded a competitive grant from the National Center for Advancing Translational Sciences (NCATS), part of the National Insti...
Philips, a global leader in health technology,announced a plan for new investments of more than USD 150 million in U.S. manufacturi...
-Techcyte, a leading provider of AI-powered digital diagnostics for anatomic and clinical pathology, announced that its platform, Techcyte Fusion&t...
Kexing Biopharm (688136.SH) has officially entered into a comprehensive strategic partnership with IQVIA(NYSE:IQV), a global leader in clinica...
Fosun Pharma (SSE:600196, HKEX: 02196) announced that its subsidiary Fosun Pharma Industrial has signed a License Agreement with Expedition Therapeutics ...
Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to th...
HERNEXEOS® (zongertinib tablets) approved based on an objective response rate of 75% (N=71), as demonstrated in the Beamion-LUNG 1 clinical trial ...
© 2025 Biopharma Boardroom. All Rights Reserved.
